Transarterial chemoembolization combined with lenvatinib and camrelizumab for unresectable hepatocellular carcinoma: A prospective, single-arm, multicenter study.

医学 伦瓦提尼 肝细胞癌 内科学 临床终点 不利影响 外科 肿瘤科 索拉非尼 临床试验
作者
Zhibo Zhang,Mao-Lin Yan,Yufeng Chen,Xukun Wu,Lan-Fang Yang,Zhengyu Yin,Hao Liu,Yongyi Zeng,Hui Zhang,Jinke Huang,Jiafei Chen,Liang Wang,Zhongwu Chen
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:41 (16_suppl): 4072-4072
标识
DOI:10.1200/jco.2023.41.16_suppl.4072
摘要

4072 Background: Conversion therapy for unresectable hepatocellular carcinoma (uHCC) has attracted increasing interest in recent years. In 2020 ASCO annual meeting, one abstract reported that the combination therapy of tyrosine kinase inhibitor and anti-PD-1 antibody could be a promising conversion therapy for patients with initially uHCC. This study aims to evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with lenvatinib and camrelizumab (TACE+LEN+CAM) as a conversion therapy for uHCC. Methods: This single-arm, prospective, multicenter study was conducted on patients diagnosed with HCC (with an Eastern Cooperative Oncology Group performance score (ECOG PS) of 0-1 and Child-Pugh class A) who were ineligible for surgery. Enrolled patients received camrelizumab (200 mg every 3 weeks) and lenvatinib (bodyweight ≥ 60 kg: 12 mg/day; < 60 kg: 8 mg/day) after TACE treatment. Surgery was performed after treatment response was assessed to meet the criteria of resection. Patients who did not meet the criteria for surgery continued to receive triple treatment until disease progression or intolerable toxicity. Primary endpoints were objective response rate (ORR)and safety. Secondary endpoints included percentage of patients amendable to surgery, the rate of radical (R0) resection, disease control rate (DCR). This study is registered with Chinese Clinical Trial Registry (ChiCTR2100050410). Results: Between Oct 25, 2021, and Jul 20, 2022, 55 patients were enrolled and received triple therapy (TACE+LEN+CAM). Of these, 37 (67.3%) patients had portal vein tumor thrombosis. Mean tumor diameter for all patients was 112 ± 83 mm. 52 (94.6%) patients with≤2 target lesions, and 3 (5.4%) patients with > 2 target lesions. As of data cutoff on Dec 20, 2022, the median follow-up was 6.7 months (IQR 5.0-9.89). According to modified RECIST criteria, tumor response in patients included complete response to treatment in 9 patients (18.0%), partial response in 27 (54.0%), stable disease in 6 (12.0%), and progressive disease in 7 (14.0%). The ORR was 72.0%, and the DCR was 84.0%. 26 patients underwent surgery after successful conversion therapy. The MPR and pCR rates in the surgery population were 69.2% and 23.1%, respectively. The conversion rate was 55.3% and the R0 resection rate was 100%. 23 (41.8%) of 55 patients had treatment-related adverse event (TRAEs) that were grade 3-5. No grade 3-5 TRAEs occurred after surgery. Conclusions: The triple therapy (TACE+LEN+CAM) significantly improved ORR and the surgical conversion rate of uHCC patients with a manageable safety. Future large-scale randomised trials are warranted. Clinical trial information: ChiCTR2100050410 .

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Akim的应助被科研通管家采纳,获得10
刚刚
SciGPT的应助被科研通管家采纳,获得10
刚刚
calvin发布了新的文献求助10
刚刚
谢耳朵发布了新的文献求助10
刚刚
坚强灵竹发布了新的文献求助10
刚刚
SciGPT的应助被科研通管家采纳,获得10
刚刚
刚刚
1秒前
Henry发布了新的文献求助10
1秒前
Akim的应助被LGTOCQ采纳,获得10
1秒前
汉堡包的应助被科研通管家采纳,获得10
1秒前
STARRY发布了新的文献求助10
1秒前
英俊的铭的应助被科研通管家采纳,获得10
1秒前
思源的应助被科研通管家采纳,获得10
1秒前
Wefaily发布了新的文献求助20
2秒前
斯文败类的应助被科研通管家采纳,获得10
2秒前
英俊的铭的应助被科研通管家采纳,获得10
2秒前
深情安青的应助被科研通管家采纳,获得10
2秒前
Owen的应助被乐观的鞋子采纳,获得10
2秒前
英姑的应助被科研通管家采纳,获得10
2秒前
lixiang完成签到,获得积分10
2秒前
bkagyin的应助被科研通管家采纳,获得10
2秒前
充电宝的应助被不安冰烟采纳,获得10
2秒前
李爱国的应助被科研通管家采纳,获得10
2秒前
王阳辉完成签到,获得积分10
2秒前
搜集达人的应助被科研通管家采纳,获得10
2秒前
酷波er的应助被科研通管家采纳,获得10
3秒前
香蕉觅云的应助被科研通管家采纳,获得10
3秒前
传奇3的应助被科研通管家采纳,获得10
3秒前
皇后完成签到,获得积分10
3秒前
田様的应助被科研通管家采纳,获得10
3秒前
飞龙发布了新的文献求助10
3秒前
星辰大海的应助被科研通管家采纳,获得10
3秒前
3秒前
3秒前
JamesPei的应助被科研通管家采纳,获得10
3秒前
3秒前
Nameless完成签到,获得积分10
3秒前
4秒前
cy完成签到,获得积分10
4秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Handbook of Pharmaceutical Excipients. 9th ed 400
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
Breaking the World 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8155737
求助须知:如何正确求助?哪些是违规求助? 9552018
关于积分的说明 21707687
捐赠科研通 7744923
什么是DOI,文献DOI怎么找? 3426177
关于科研通互助平台的介绍 2551229
邀请新用户注册赠送积分活动 2469949